After reading this note you will be able to describe the clinical approach to a patient with acute or chronic pancreatitis, list relevant local aetiologies, interpret key investigations and outline immediate and definitive management – remembering to verify drug choices and doses against the Kenya MoH guideline and your hospital formulary.
Definition
- Acute pancreatitis (AP): A sudden inflammation of the pancreas presenting with abdominal pain and/or enzyme elevation, which may be self‑limiting or progress to necrotising disease.
- Chronic pancreatitis (CP): Persistent inflammation leading to irreversible structural damage, fibrosis and loss of exocrine/endocrine function, often with recurrent attacks.
Anatomy and physiology you need
| Structure | Relevance to disease |
|---|---|
| Pancreatic head, body, tail | Site of enzyme production; obstruction (e.g., stone, tumour) most often at the head |
| Ductal system (main pancreatic duct, accessory duct) | Blockage raises intraductal pressure → acinar injury |
| Acinar cells | Synthesize digestive enzymes; premature activation triggers autodigestion |
| Islet cells | Endocrine loss in CP → diabetes mellitus |
| Sphincter of Oddi | Dysfunction can cause reflux of duodenal contents into pancreas |
| Peripancreatic fat & retroperitoneum | Site of necrosis and fluid collections in severe AP |
Causes and risk factors
| Category | Common in Kenya | Why it matters |
|---|---|---|
| Alcohol | Heavy local brews, spirits | Direct toxic effect on acinar cells, promotes ductal spasm |
| Gallstones | Biliary disease prevalent | Obstructs ampulla → sudden rise in ductal pressure |
| Hypertriglyceridaemia | Poorly controlled diabetes, diet | TG >1000 mg/dL cause free fatty acid toxicity |
| HIV infection / ART | Protease inhibitors, immune activation | Drug‑induced pancreatitis; HIV itself may infiltrate pancreas |
| Tuberculosis | Extrapulmonary TB | Peripancreatic TB nodes can compress ducts |
| Malaria (severe) | Plasmodium falciparum | Microvascular obstruction, cytokine surge |
| Sickle cell disease | Vaso‑occlusive crises | Ischaemia of pancreatic microcirculation |
| Autoimmune pancreatitis | IgG4‑related disease | Lymphoplasmacytic infiltration, responds to steroids |
| Medications | Didanosine, azathioprine, tetracyclines, antiretrovirals | Direct toxic or hypersensitivity mechanisms |
| Genetic predisposition | PRSS1, SPINK1 mutations (rare) | Early‑onset CP, especially in families |
| Trauma | Road‑traffic accidents, blunt abdominal injury | Direct ductal disruption |
Pathophysiology
Acute pancreatitis
Biliary stone or alcohol → ↑ ductal pressure / sphincter spasm → premature trypsinogen activation inside acinar cells → intracellular trypsin → autodigestion → inflammatory cascade (cytokines, neutrophil influx) → edema, necrosis, systemic inflammatory response.
Chronic pancreatitis
Repeated acute insults (alcohol, stones, hypertriglyceridaemia) → persistent activation of pancreatic enzymes → fibrosis (stellate cell activation) → loss of acinar tissue → exocrine insufficiency (steatorrhea) + endocrine loss (diabetes) → ductal strictures → further obstruction → cycle continues.
Arrows representation
``` Risk factor → Ductal obstruction / acinar injury → Premature enzyme activation → Autodigestion → Inflammation → Edema/necrosis (AP) → Fibrosis (CP) → Exocrine & endocrine failure
Clinical features
| Aspect | Key questions / findings | Why it occurs |
|---|---|---|
| Onset & timing | Sudden vs gradual pain; hours to days for acute, months‑years for chronic | Acute inflammation produces rapid enzymatic injury; chronic disease reflects ongoing fibrosis and ductal obstruction |
| Pain character | Severe epigastric pain radiating to the back, “boring” or “knife‑like”, worsened by meals or lying supine, relieved by leaning forward | Stretch of the inflamed pancreas and irritation of retroperitoneal nerves; forward flexion reduces intra‑abdominal pressure on the gland |
| Meal relation | Pain after fatty meals, alcohol binge, or fasting | Fat stimulates pancreatic secretion; alcohol and fasting both trigger premature enzyme activation |
| Associated symptoms | Nausea, vomiting, early satiety, weight loss, steatorrhea (large foul‑smelling stools), new‑onset diabetes, fever, chills | Vomiting from visceral irritation; malabsorption from exocrine insufficiency; loss of β‑cell mass → hyperglycaemia; systemic inflammation → fever |
| Alcohol & toxin exposure | Quantity and pattern of alcohol intake, use of herbal medicines, exposure to pesticides, recent antiretroviral therapy, TB treatment | Alcohol is the dominant cause in adults; some drugs (e.g., didanosine, protease inhibitors) and toxins precipitate pancreatitis in the Kenyan setting |
| Infectious history | Recent malaria, HIV infection, TB, hepatitis, or schistosomiasis; recent travel to endemic areas | HIV, TB, malaria and some parasitic infections can cause pancreatic inflammation directly or via drug toxicity |
| Haematologic & rheumatic background | Sickle‑cell disease, autoimmune disorders (e.g., systemic lupus), recent transfusion | Sickle‑cell vaso‑occlusion can infarct pancreatic tissue; autoimmune pancreatitis presents with IgG4‑related disease |
| Past pancreatic disease | Prior episodes, known gallstones, previous ERCP, pancreatic surgery | Recurrent gallstone obstruction or iatrogenic injury predisposes to repeat attacks |
| Systemic signs | Jaundice, pruritus, dark urine, pale stools | Obstruction of the common bile duct by pancreatic head swelling or stones |
| Examination – abdomen | Tenderness in epigastrium, guarding, possible palpable mass in chronic disease, decreased bowel sounds | Inflammation irritates peritoneum; chronic fibrosis may produce a firm, irregular mass |
| Examination – systemic | Fever, tachycardia, hypotension, signs of dehydration, peripheral edema, pleural effusion, ascites | Systemic inflammatory response; third‑space fluid shifts; severe pancreatitis can cause capillary leak |
| Examination – skin | Xanthomas, necrotic skin lesions, livedo reticularis | Hypertriglyceridaemia‑related pancreatitis or vasculitic processes |
| Examination – respiratory | Tachypnoea, decreased breath sounds at bases | Pleural effusion or atelectasis secondary to diaphragmatic irritation |
Differential diagnosis
| Condition | Points toward it | What separates it from pancreatitis |
|---|---|---|
| Acute cholecystitis | RUQ pain, fever, Murphy’s sign, gallstones on US | Pain localized to RUQ, improves on leaning forward, gallbladder wall thickening without pancreatic enzyme rise |
| Peptic ulcer disease / perforated ulcer | Epigastric pain related to meals, melena, free air on X‑ray | Pain relieved by antacids, no lipase elevation, pneumoperitoneum on imaging |
| Biliary colic / choledocholithiasis | Post‑prandial RUQ pain, jaundice, CBD stones on US | Intermittent pain, normal pancreatic enzymes unless pancreatitis co‑exists |
| Acute mesenteric ischemia | Sudden severe pain out of proportion, risk factors (AF, atherosclerosis) | Pain disproportionate to exam, lactate rise, CTA shows arterial occlusion |
| Hepatitis / hepatic abscess | Right upper quadrant pain, hepatomegaly, abnormal LFTs, fever | Predominant liver enzyme elevation, imaging shows hepatic lesions |
| Infectious gastroenteritis | Diarrhoea, vomiting, recent outbreak exposure | No epigastric radiation, normal lipase, stool studies positive |
| Sickle‑cell vaso‑occlusive crisis | Known sickle‑cell disease, pain in multiple sites, hemolysis | Pain often in long bones, sickled cells on smear, crisis may involve pancreas but usually accompanied by other crises |
| Autoimmune pancreatitis | Middle‑aged male, painless jaundice, IgG4 elevation | Diffuse pancreatic enlargement, response to steroids, lack of acute pain |
Investigations
| Test | What it answers | Interpretation |
|---|---|---|
| Serum amylase & lipase | Enzyme release from injured acinar cells | Lipase >3× ULN is most specific for pancreatitis; amylase may rise in other abdominal conditions |
| Full blood count | Inflammation, infection, anemia | Leukocytosis → systemic inflammation; anemia may suggest chronic disease or haemolysis |
| Electrolytes, renal & liver panel | Metabolic derangements, biliary obstruction | Elevated bilirubin & ALP → biliary involvement; hypocalcaemia may signal severe necrosis |
| Serum triglycerides | Hypertriglyceridaemia as a cause | >11 mmol/L strongly implicates triglyceride‑induced pancreatitis |
| HIV, hepatitis B/C serology | Underlying infection or drug‑related toxicity | Positive HIV may point to opportunistic pancreatitis or ART toxicity |
| IgG4 level | Autoimmune pancreatitis | Markedly raised IgG4 supports type 1 autoimmune pancreatitis |
| Abdominal ultrasound (FAST) | Gallstones, biliary dilatation, fluid collections | Gallstones present → biliary pancreatitis; fluid suggests ascites or peripancreatic collection |
| Contrast‑enhanced CT (CECT) abdomen (48‑72 h) | Extent of necrosis, fluid collections, vascular complications | Non‑enhancing pancreas >30 % → necrotizing pancreatitis; identifies pseudocysts |
| MRCP / Endoscopic US | Ductal anatomy, stones in pancreatic duct, strictures | Dilated pancreatic duct with stones → obstructive cause; smooth tapering suggests autoimmune disease |
| Endoscopic retrograde cholangiopancreatography (ERCP) | Therapeutic stone removal, ductal stenting | Reserved for cholangitis or persistent biliary obstruction |
| Serum calcium, phosphate, magnesium | Metabolic complications | Hypocalcaemia in severe disease; hyperphosphataemia may indicate renal failure |
Diagnosis and severity
Diagnostic criteria (Atlanta 2012) – Diagnosis is made when two of three are present:
- Typical abdominal pain (acute epigastric pain radiating to the back).
- Serum lipase (or amylase) ≥ 3 times the upper limit of normal.
- Imaging showing pancreatic inflammation (CT, MRI, or US).
If only one criterion is met, repeat testing after 24 h or obtain imaging.
Severity grading (revised Atlanta classification)
| Category | Clinical / laboratory markers | Management implications |
|---|---|---|
| Mild | No organ failure, no local or systemic complications | Early oral feeding as tolerated, routine monitoring |
| Moderately severe | Transient organ failure (<48 h) or local complications (peripancreatic fluid, necrosis, pseudocyst) | Close ICU/ward observation, fluid resuscitation, early enteral nutrition, consider antibiotics if infected necrosis |
| Severe | Persistent organ failure (>48 h) involving respiratory, cardiovascular or renal systems | Admit to high‑dependency/ICU, aggressive fluid management, vasopressor support, renal replacement if needed, early multidisciplinary input (surgery, radiology, nutrition) |
Key bedside severity clues
- SIRS (temperature >38 °C or <36 °C, HR >90, RR >20, WBC >12 × 10⁹/L) → predicts severe disease.
- Hypotension despite fluid bolus → early organ dysfunction.
- Elevated hematocrit on admission (>44 %) → hemoconcentration, higher risk of necrosis.
- BUN rise >5 mg/dL within 24 h → renal hypoperfusion, marker of severe disease.
Chronic pancreatitis is diagnosed when there is persistent pancreatic insufficiency (exocrine or endocrine) plus imaging evidence of irreversible changes (calcifications, ductal irregularities, atrophy). Severity is staged by the M-ANNHEIM system, focusing on pain, endocrine/exocrine failure, and complications; in practice, the presence of steatorrhea, weight loss, or diabetes guides long‑term management.
End of part 2.
Management
Immediate stabilisation
| Step | Rationale |
|---|---|
| Airway, breathing, circulation (ABCs) | Ensure oxygenation, treat hypotension promptly |
| Large‑bore IV access (2 × 18 G) | Allows rapid fluid resuscitation and drug administration |
| Aggressive isotonic crystalloid (e.g., normal saline) – give until urine output ≥0.5 mL/kg/h | Reverses third‑spacing, improves pancreatic microcirculation |
| Analgesia (opioid or NSAID) titrated to pain score | Reduces sympathetic stress, facilitates breathing |
| NPO (nil per os) and nasogastric tube if vomiting or ileus | Limits pancreatic stimulation |
| Early assessment for organ failure (renal, respiratory, cardiovascular) | Guides severity scoring and ICU need |
Definitive treatment – tailored to aetiology and severity
Acute pancreatitis
- Fluid optimisation continued for 48 h, then switch to maintenance once stable.
- Enteral nutrition within 24–48 h (nasogastric or naso‑jejunal) – lowers infection risk compared with parenteral feeding.
- Etiology‑directed therapy
- Gallstone disease: urgent ERCP with sphincterotomy if cholangitis or persistent biliary obstruction; otherwise, cholecystectomy during same admission (if mild) or after recovery (if severe).
- Alcohol: counselling, referral for de‑addiction services.
- Hypertriglyceridaemia: insulin infusion or apheresis where available.
- Drug‑induced: stop offending agent.
- HIV/TB‑related: optimise antiretroviral/anti‑TB regimen, consider drug‑induced pancreatitis.
- Antibiotics only if proven infected necrosis or extrapancreatic infection; choose broad‑spectrum covering gram‑negatives and anaerobes (e.g., carbapenem or β‑lactam/β‑lactamase inhibitor).
- Pancreatic enzyme suppression – avoid routine use of octreotide; reserved for refractory cases.
Chronic pancreatitis
- Pain control – stepwise analgesic ladder, consider neuropathic agents (e.g., gabapentinoids) for persistent pain.
- Pancreatic enzyme replacement (enteric‑coated lipase, amylase, protease) with meals to improve malabsorption and reduce pain.
- Fat‑soluble vitamin supplementation (A, D, E, K) when steatorrhea present.
- Endoscopic therapy – pancreatic duct stenting for dominant strictures; lithotripsy for obstructing stones.
- Surgical options – lateral pancreaticojejunostomy (Puestow) for ductal dilatation, or resection for localized disease.
- Lifestyle – strict abstinence from alcohol and smoking cessation; nutritional counselling.
Monitoring & safety
- Vital signs, urine output, and fluid balance hourly (first 24 h).
- Daily labs: CBC, electrolytes, renal function, calcium, glucose, liver enzymes, serum amylase/lipase, CRP.
- Serial abdominal exam for peritoneal signs.
- Imaging (repeat US/CT) if clinical deterioration or suspicion of necrosis/infection.
- Watch for hypocalcaemia, hyperglycaemia, and acute kidney injury; treat promptly.
- Contra‑indications: avoid routine prophylactic antibiotics, avoid early aggressive enteral feeding in patients with ileus, avoid NSAIDs in renal failure or active GI bleed.
Complications and prognosis
- Local: pancreatic necrosis, pseudocyst, walled‑off necrosis, pancreatic fistula, splenic vein thrombosis.
- Systemic: acute respiratory distress syndrome, renal failure, shock, disseminated intravascular coagulation, hyperglycaemia/diabetes mellitus.
- Chronic sequelae: exocrine insufficiency (steatorrhea, weight loss), endocrine insufficiency (type 3c diabetes), chronic pain, increased risk of pancreatic carcinoma.
- Prognosis – depends on severity (Ranson, APACHE‑II, BISAP). Mild disease resolves in <1 week; severe disease carries 20–30 % mortality, higher with infected necrosis. Early aggressive fluid therapy and timely source control improve outcomes.
High‑yield exam points
- Look‑alike conditions: duodenal ulcer perforation, biliary colic, mesenteric ischemia, acute cholecystitis.
- Common wrong first step: giving routine antibiotics before confirming infected necrosis.
- Bedside examiner questions:
- “What is the first thing you do for a patient with suspected acute pancreatitis?” (Answer: ABCs and aggressive IV fluids).
- “How do you differentiate gallstone‑related from alcoholic pancreatitis clinically?” (Answer: history of recent fatty meals, RUQ pain, gallstones on US vs. chronic alcohol use, malnutrition).
- “When is ERCP indicated in acute pancreatitis?” (Answer: suspected cholangitis or persistent biliary obstruction).
- “What are the indications for surgical intervention in chronic pancreatitis?” (Answer: refractory pain, ductal obstruction, or suspicion of malignancy).
Clinical case
Case: 42‑year‑old male farmer, chronic alcoholic, presents with 12 h of epigastric pain radiating to the back, vomiting, and a tender, distended abdomen. No fever. Vitals: BP 100/60 mmHg, HR 110 bpm, RR 22, SpO₂ 96 % on room air. Labs: serum amylase 5× ULN, lipase 7× ULN, CRP 150 mg/L, creatinine 150 µmol/L (baseline 90). US shows a distended gallbladder with sludge, no stones.
Questions
- What is the immediate next step?
Answer: Initiate aggressive IV crystalloid resuscitation and keep the patient NPO while obtaining analgesia.
- What severity score would you apply and what does it indicate?
Answer: BISAP (BUN, Impaired mental status, SIRS, Age > 60, Pleural effusion). A score ≥ 3 predicts higher risk of mortality; this patient scores 2 (SIRS, BUN elevation), indicating moderate severity.
- What definitive management is indicated for this patient?
Answer: Because gallbladder sludge suggests biliary aetiology, arrange early ERCP with sphincterotomy if cholangitis develops; otherwise, plan cholecystectomy after clinical improvement.
Practice questions
Question 1
A 55‑year‑old woman with known HIV on antiretroviral therapy presents with sudden epigastric pain, nausea, and a serum lipase 8× ULN. She is afebrile, BP 130/80, HR 95. What is the most appropriate next step?
A. Start broad‑spectrum antibiotics
B. Immediate CT abdomen with contrast
C. Begin aggressive IV fluid resuscitation
D. Schedule elective cholecystectomy
Answer: C. Begin aggressive IV fluid resuscitation
Explanation: Early fluid therapy improves outcomes; antibiotics are reserved for infected necrosis, and imaging is delayed unless deterioration occurs.
Question 2
A patient with chronic pancreatitis develops new‑onset jaundice and right‑upper‑quadrant pain. Which investigation best distinguishes a pancreatic head mass from a biliary stone obstruction?
A. Abdominal X‑ray
B. Endoscopic ultrasound (EUS)
C. Plain abdominal ultrasound
D. Serum CA‑19‑9
Answer: B. Endoscopic ultrasound (EUS)
Explanation: EUS provides high‑resolution imaging of the pancreas and can guide fine‑needle aspiration, differentiating mass from stone disease.
Question 3
In severe acute pancreatitis with necrotic collection, why is early enteral feeding preferred over total parenteral nutrition?
A. It reduces the risk of line‑related sepsis
B. It accelerates pancreatic enzyme secretion
C. It increases the chance of developing hyperglycaemia
D. It eliminates the need for analgesia
Answer: A. It reduces the risk of line‑related sepsis
Explanation: Early enteral nutrition maintains gut barrier function and lowers infection rates compared with parenteral routes.
Question 4
A 30‑year‑old male with sickle cell disease presents with abdominal pain and a serum amylase 3× ULN. Which of the following is the most likely precipitating factor in this setting?
A. Gallstones
B. Hypertriglyceridaemia secondary to transfusion‑related lipid overload
C. Vaso‑occlusive crisis causing pancreatic ischaemia
D. Antimalarial medication
Answer: C. Vaso‑occlusive crisis causing pancreatic ischaemia
Explanation: Sickle cell disease can cause pancreatic ischaemia during crisis, leading to pancreatitis.
Question 5
A patient with acute pancreatitis develops a pleural effusion on the left side. Which severity marker does this represent?
A. Ranson’s age criterion
B. BISAP pleural effusion item
C. APACHE‑II respiratory score
D. Glasgow‑Imrie calcium level
Answer: B. BISAP pleural effusion item
Explanation: Presence of a pleural effusion is one of the five BISAP criteria and predicts higher mortality.
Drafted with AI assistance from standard references and reviewed for structure. Check details against your lecture notes and the Kenya MoH guideline.